<DOC>
	<DOCNO>NCT00891033</DOCNO>
	<brief_summary>Multiple myeloma ( MM ) account approximately 1 % malignancy 10 % hematological tumor , represent second frequently occur hematological malignancy United States . At one time , 50,000 people suffer MM , approximately 15,000 diagnosed year . The median age approximately 65 year , although occasionally MM occur second decade life . Bortezomib panobinostat intravenous ( IV ) active agent multiple myeloma appear work different biochemical pathway , suggest may synergistic effect use combination . Both compound show anabolic bone effect , associate significant anti-myeloma activity . Primary objective : - To assess toxicity bortezomib combine one 4 dos panobinostat IV patient relapsed/refractory multiple myeloma , - To find appropriate dos bortezomib panobinostat IV combination . Secondary objective : - To assess effect bortezomib combination panobinostat IV induce osteoblast activation patient relapsed/refractory myeloma .</brief_summary>
	<brief_title>Panobinostat/Velcade Multiple Myeloma</brief_title>
	<detailed_description>The objective study identify maximum tolerate dose ( MTD ) ass feasibility toxicity experience patient refractory multiple myeloma treat bortezomib one three dos panobinostat IV . Sample Size : This study accrue 24 patient , 4 group 6 patient , depend experience DLT . Patients studied follow , Group 1 : Bortezomib 1.0 mg/m2 panobinostat IV 5 mg/m2 IV , Group 2 : Bortezomib 1.0 mg/m2and panobinostat IV 10 mg/m2 IV , Group 3 : Bortezomib 1.0 mg/m2 panobinostat IV 15 mg/m2 IV Group 4 : Bortezomib 1.0 mg/m2 panobinostat IV 20 mg/m2 IV . Bortezomib give day 1 , 4 , 8 , 11 cycle 1 cycle 2 , panobinostat give day 1 8 second cycle . If MTD reach first group , second group enrol receive bortezomib1.0 mg/m2 escalation panobinostat IV describe . Patient population : Patient 's relapsed/refractory multiple myeloma least one line prior therapy . Inclusion exclusion criterion : Patients must baseline evaluation perform prior first dose study drug must meet inclusion exclusion criterion . Results baseline evaluation , assure inclusion exclusion criterion satisfy , must review principal investigator prior enrollment patient . In addition , patient must thoroughly inform aspect study , include study visit schedule require evaluation regulatory requirement inform consent . The write informed consent must obtain patient prior enrollment . The following criterion apply patient enrol onto study unless otherwise specify .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>1 . Patients relapsed/refractory multiple myeloma least one line prior therapy 2 . Male female patient age ≥ 18 year old 3 . Ability provide write informed consent obtain prior participation study relate procedure perform 4 . Patients allow receive growth factor ( erythropoietin hormone , GCSF GMCSF ) 5 . Patients must meet follow laboratory criterion : ANC ≥ 1.5 x 109/L Hemoglobin ≥ 9 g/dl Platelets ≥ 100x 109/L Calculated CrCl &gt; 50 mL/min ( MDRD Formula ) AST ALT ≤ 2.5 x ULN Serum bilirubin &lt; 2.0 x ULN Albumin &gt; 3.0 g/dl Serum potassium ≥ LLN institution Total serum calcium [ correct serum albumin ] ionize calcium ≥LLN , institution Serum magnesium ≥ LLN institution Serum phosphorus ≥ LLN institution TSH ≤ LLN free T4 within normal limit . Patients permit receive thyroid hormone supplement treat underlying hypothyroidism 6 . Baseline MUGA ECHO must demonstrate LVEF ≥ low limit institutional normal 7 . History histologically document MM relapse progressive disease least one line prior therapy 8 . Patient measurable disease capture response , define one following : 1 . Serum Mprotein level ≥ 0.5 gm/dl ( 10.0 g/L ) measure serum protein electrophoresis immunoglobulin electrophoresis ; 2 . Urinary Mprotein excretion ≥ 200 mg/24 hr ; 3 . Bone marrow plasmacytosis ≥ 30 % bone marrow aspirate and/or biopsy ; 4 . Serum Free Light Chains ( By Freelite test ) &gt; 2X ULN , absence renal failure 9 . Performance status ≤ 2 per ECOG scale , unless PS 34 base solely bone pain 10 . Patients must sign IRB approve write informed consent form demonstrate willingness meet followup schedule study procedure obligation 1 . Prior HDAC , DAC , HSP90 inhibitor valproic acid treatment cancer 2 . Patients receive Velcade within 2 month enrollment 3 . Patients need valproic acid medical condition study within 5 day prior first panobinostat IV treatment 4 . Peripheral neuropathy &gt; grade 2 . 5 . Impaired cardiac function clinically significant cardiac disease , include one following : Patients congenital long QT syndrome History presence sustain ventricular tachyarrhythmia . ( Patients history atrial arrhythmia eligible discuss Novartis prior enrollment ) Any history ventricular fibrillation torsade de pointes Bradycardia define HR &lt; 50 bpm . Patients pacemaker eligible HR ≥ 50 bpm . Screening ECG QTc &gt; 450 msec Right bundle branch block + leave anterior hemiblock ( bifascicular block ) Patients myocardial infarction unstable angina ≤ 6 month prior start study drug Other clinically significant heart disease ( e.g. , CHF NY Heart Association class III IV , uncontrolled hypertension , history labile hypertension , history poor compliance antihypertensive regimen ) 6 . Other concurrent severe and/or uncontrolled medical condition ( e.g. , uncontrolled diabetes active uncontrolled infection ) include abnormal laboratory value , could cause unacceptable safety risk compromise compliance protocol 7 . Patients use medication relative risk prolong QT interval induce torsade de pointes treatment discontinue switched different medication prior start study drug 8 . Concomitant use CYP3A4 inhibitor ( See Appendix 2 ) 9 . Patients receive targeted agent within 2 week within 5 halflives agent active metabolite ( ever longer ) recover side effect therapy . 10 . Patients receive either immunotherapy ( e.g . vaccine ) within &lt; 8 week ; chemotherapy within &lt; 4 week ; radiation therapy &gt; 30 % marrowbearing bone within &lt; 2 week prior start study treatment ; yet recover side effect therapy . 11 . Patients active bleeding tendency receive treatment therapeutic dos sodium warfarin ( Coumadin® ) coumadin derivative . Low dos Coumadin® ( e.g . ≤ 2.0 mg/day ) maintain line patency ( applicable ) allow . 12 . Patients undergone major surgery ≤ 4 week prior start study drug recover side effect therapy 13 . Women pregnant breast feed woman childbearing potential ( WOCBP ) use effective method birth control . WOCBP define sexually mature woman undergone hysterectomy naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) . Women childbearing potential must negative serum pregnancy test within 24hrs receive first dose study medication . 14 . Male patient whose sexual partner WOCBP use effective birth control 15 . Patients prior malignancy last 5 year ( except basal squamous cell carcinoma , situ cancer cervix ) 16 . Patients know positivity human immunodeficiency virus ( HIV ) ) hepatitis C ; baseline test HIV hepatitis C require 17 . Patients significant history noncompliance medical regimen unwilling unable comply instruction give him/her study staff . 18 . No concomitant use bisphosphonates allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>cancer</keyword>
</DOC>